FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2575872007> ?p ?o ?g. }

• W2575872007 abstract "Defensins are small antimicrobial peptides capable of neutralizing human adenovirus (HAdV) in vitro by binding capsid proteins and blocking endosomal escape of virus. In humans, the alpha defensin HD5 is produced by specialized epithelial cells of the gastrointestinal and genito-urinary tracts. Here, we demonstrate, using patient biopsy specimens, that HD5 is also expressed as an active, secreted peptide by epithelial ovarian and lung cancer cells in situ This finding prompted us to study the role of HD5 in infection and spread of replication-competent, oncolytic HAdV type 3 (HAdV3). HAdV3 produces large amounts of penton-dodecahedra (PtDd), virus-like particles, during replication. We have previously shown that PtDd are involved in opening epithelial junctions, thus facilitating lateral spread of de novo-produced virions. Here, we describe a second function of PtDd, namely, the blocking of HD5. A central tool to prove that viral PtDd neutralize HD5 and support spread of progeny virus was an HAdV3 mutant virus in which formation of PtDd was disabled (mut-Ad3GFP, where GFP is green fluorescent protein). We demonstrated that viral spread of mut-Ad3GFP was blocked by synthetic HD5 whereas that of the wild-type (wt) form (wt-Ad3GFP) was only minimally impacted. In human colon cancer Caco-2 cells, induction of cellular HD5 expression by fibroblast growth factor 9 (FGF9) significantly inhibited viral spread and progeny virus production of mut-Ad3GFP but not of wt-Ad3GFP. Finally, the ectopic expression of HD5 in tumor cells diminished the in vivo oncolytic activity of mut-Ad3GFP but not of wt-Ad3GFP. These data suggest a new mechanism of HAdV3 to overcome innate antiviral host responses. Our study has implications for oncolytic adenovirus therapy.IMPORTANCE Previously, it has been reported that human defensin HD5 inactivates specific human adenoviruses by binding to capsid proteins and blocking endosomal escape of virus. The central new findings described in our manuscript are the following: (i) the discovery of a new mechanism used by human adenovirus serotype 3 to overcome innate antiviral host responses that is based on the capacity of HAdV3 to produce subviral penton-dodecahedral particles that act as decoys for HD5, thus preventing the inactivation of virus progeny produced upon replication; (ii) the demonstration that ectopic HD5 expression in cancer cells decreases the oncolytic efficacy of a serotype 5-based adenovirus vector; and (iii) the demonstration that epithelial ovarian and lung cancers express HD5. The study improves our understanding of how adenoviruses establish infection in epithelial tissues and has implications for cancer therapy with oncolytic adenoviruses." @default.
• W2575872007 created "2017-01-26" @default.
• W2575872007 creator A5002338107 @default.
• W2575872007 creator A5002698591 @default.
• W2575872007 creator A5012809255 @default.
• W2575872007 creator A5028288310 @default.
• W2575872007 creator A5029285661 @default.
• W2575872007 creator A5031342042 @default.
• W2575872007 creator A5054774521 @default.
• W2575872007 creator A5056305765 @default.
• W2575872007 creator A5057049857 @default.
• W2575872007 creator A5057803071 @default.
• W2575872007 creator A5067585305 @default.
• W2575872007 creator A5086739537 @default.
• W2575872007 creator A5086796397 @default.
• W2575872007 date "2017-03-15" @default.
• W2575872007 modified "2023-10-16" @default.
• W2575872007 title "Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy" @default.
• W2575872007 cites W1597583781 @default.
• W2575872007 cites W1819766659 @default.
• W2575872007 cites W1967114714 @default.
• W2575872007 cites W1968929452 @default.
• W2575872007 cites W1981257554 @default.
• W2575872007 cites W1995243829 @default.
• W2575872007 cites W1998506044 @default.
• W2575872007 cites W2004473148 @default.
• W2575872007 cites W2013743238 @default.
• W2575872007 cites W2018308755 @default.
• W2575872007 cites W2029980168 @default.
• W2575872007 cites W2034752006 @default.
• W2575872007 cites W2035068250 @default.
• W2575872007 cites W2039510422 @default.
• W2575872007 cites W2048498897 @default.
• W2575872007 cites W2063495253 @default.
• W2575872007 cites W2065881418 @default.
• W2575872007 cites W2065904022 @default.
• W2575872007 cites W2077591615 @default.
• W2575872007 cites W2080421046 @default.
• W2575872007 cites W2087899417 @default.
• W2575872007 cites W2092687266 @default.
• W2575872007 cites W2121300496 @default.
• W2575872007 cites W2129656154 @default.
• W2575872007 cites W2130228485 @default.
• W2575872007 cites W2134119060 @default.
• W2575872007 cites W2134935858 @default.
• W2575872007 cites W2142081300 @default.
• W2575872007 cites W2146812359 @default.
• W2575872007 cites W2151456025 @default.
• W2575872007 cites W2163663325 @default.
• W2575872007 cites W2309022513 @default.
• W2575872007 cites W2339396473 @default.
• W2575872007 cites W2494461917 @default.
• W2575872007 cites W3022997872 @default.
• W2575872007 cites W4211238487 @default.
• W2575872007 cites W4229533301 @default.
• W2575872007 doi "https://doi.org/10.1128/jvi.02030-16" @default.
• W2575872007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5331826" @default.
• W2575872007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28077642" @default.
• W2575872007 hasPublicationYear "2017" @default.
• W2575872007 type Work @default.
• W2575872007 sameAs 2575872007 @default.
• W2575872007 citedByCount "19" @default.
• W2575872007 countsByYear W25758720072017 @default.
• W2575872007 countsByYear W25758720072018 @default.
• W2575872007 countsByYear W25758720072019 @default.
• W2575872007 countsByYear W25758720072020 @default.
• W2575872007 countsByYear W25758720072021 @default.
• W2575872007 countsByYear W25758720072022 @default.
• W2575872007 countsByYear W25758720072023 @default.
• W2575872007 crossrefType "journal-article" @default.
• W2575872007 hasAuthorship W2575872007A5002338107 @default.
• W2575872007 hasAuthorship W2575872007A5002698591 @default.
• W2575872007 hasAuthorship W2575872007A5012809255 @default.
• W2575872007 hasAuthorship W2575872007A5028288310 @default.
• W2575872007 hasAuthorship W2575872007A5029285661 @default.
• W2575872007 hasAuthorship W2575872007A5031342042 @default.
• W2575872007 hasAuthorship W2575872007A5054774521 @default.
• W2575872007 hasAuthorship W2575872007A5056305765 @default.
• W2575872007 hasAuthorship W2575872007A5057049857 @default.
• W2575872007 hasAuthorship W2575872007A5057803071 @default.
• W2575872007 hasAuthorship W2575872007A5067585305 @default.
• W2575872007 hasAuthorship W2575872007A5086739537 @default.
• W2575872007 hasAuthorship W2575872007A5086796397 @default.
• W2575872007 hasBestOaLocation W25758720071 @default.
• W2575872007 hasConcept C104317684 @default.
• W2575872007 hasConcept C111599444 @default.
• W2575872007 hasConcept C140704245 @default.
• W2575872007 hasConcept C150903083 @default.
• W2575872007 hasConcept C153911025 @default.
• W2575872007 hasConcept C159047783 @default.
• W2575872007 hasConcept C207001950 @default.
• W2575872007 hasConcept C2522874641 @default.
• W2575872007 hasConcept C2776954459 @default.
• W2575872007 hasConcept C54355233 @default.
• W2575872007 hasConcept C55493867 @default.
• W2575872007 hasConcept C81885089 @default.
• W2575872007 hasConcept C82210918 @default.
• W2575872007 hasConcept C86803240 @default.
• W2575872007 hasConcept C95444343 @default.
• W2575872007 hasConceptScore W2575872007C104317684 @default.

• next